Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses Androgen Deprivation Therapy. Androgen Deprivation Therapy is the gold standard for men with metastatic prostate cancer in addition to docetaxel based therapy.

ADT typically instituted early and has been shown to delay the onset of complication of those with metastatic disease.

However, it has limitations, and is not curative and is associated with the emergence of resistance and progression of disease.

Related Reading
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S, Logothetis C, Sternberg CN, Oudard S.
BJU Int. 2011 Apr;107 Suppl 2:13-20.